← All Cerus CORP filings

Cerus CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
CERS
Cerus CORP
10-K: Cerus Reports Revenue Growth, Narrowed Losses in 2025
Cerus Corporation saw product and government contract revenue increase in 2025, leading to a reduction in net loss, despite ongoing regulatory challenges for its red blood cell system and significant debt obligations.
NASDAQ
CERS
Cerus CORP
10-K: Cerus Corp. Files 10-K: Details Pathogen Reduction System Development and Commercialization
Cerus Corporation's 10-K filing outlines the company's efforts in developing and commercializing its INTERCEPT Blood System, including progress, risks, and financial performance.
NASDAQ
CERS
Cerus CORP
10-K: Cerus Corporation Outlines Capital Structure and Regulatory Landscape in 10-K Filing
Cerus Corporation's 10-K filing details its capital stock, potential takeover defenses, and regulatory environment, highlighting the complexities of its business.